Cingulate is trading at $5.39, up 11.31% in pre-market, with no identified company-specific catalyst. - The company’s official press-release page lists September 17, 2026, as its latest release. - The latest readily identifiable company news was an October 2 notice about extending its chief medical officer’s trial employment period. - Healthcare’s pre-market strength may provide supportive sector context, but the information does not establish it as the cause of this move.